EANM has also obtained international recognition for its annual congress[2] and for its European School of Multimodality Imaging & Therapy (ESMIT), launched in 2015 in Vienna, Austria. Additionally, EANM launched in 2025 its own two open-access, online-only, peer-reviewed medical journals — the EANM Journal[3] and EANM Innovation[4] — published by the world-leading publisher Elsevier.[5]
History
EANM was founded in 1985 in London, United Kingdom following the union of the Society of Nuclear Medicine Europe and the European Nuclear Medicine Society.[6]
EANM is governed by an elected Board of international experts in nuclear medicine. The Board serves as the top executive body of the organisation. The elected Presidents, who serve a two-year mandate and represent the organisation, are supported by their team to expand EANM’s outreach.[10]
Nuclear medicine being used in many medical disciplines, the EANM volunteers are divided into Committees and Councils, which focus on promoting nuclear medicine in different areas, including:[11]
The EANM Executive Office, based in Vienna (Austria), oversees all the logistical aspects, ranging from organising scientific events, to managing publications and establishing new partnerships, and promoting the organisation among EU institutions and international organisations. The Executive Office also organises the Annual Congress and managed the ESMIT courses.[12]
Membership-wise, EANM currently comprises 40 national societies, 20 non-European affiliated societies and 2,900 individual members from 80 countries from Europe and beyond. EANM is also supported by a team of over 150 volunteers, who work within the Board, the Committees, and the Councils.[13]
The EANM Annual Congress features scientific sessions, workshops, and interactive discussions led by speakers.[14] It brings together international experts and professionals in the field of nuclear medicine to discuss the latest advancements and innovations in nuclear medicine and molecular imaging.[15]
EU Affairs
EANM closely works with EU institutions and EU policymakers to shed more light on the properties of nuclear medicine and to ensure that EU citizens have access to high-quality and safe therapeutic nuclear medicine.[16]
For instance, as part of the European Commission’s SAMIRA Action Plan, EANM is part of the consortium performing the SIMPLERAD Project, which seeks to ensure that Euratom radiation protection requirements and the EU legislation concerning the therapeutic use of radiopharmaceuticals are implemented.[17]
ESMIT
ESMIT's official logo
EANM is highly active in the field of education. Its European School of Multimodality Imaging & Therapy (ESMIT) was founded in 2015 as a response to the rising demand for educational programmes focusing on nuclear medicine.[18]
EANM launched ESMIT to equip health professionals with knowledge about both the modalities of nuclear medicine and its therapeutic applications. With the help of experienced faculty members, EANM thus offers a wide range of learning experiences, ranging from in-person advanced courses, to live webinars and an eLearning platform.[19]
EARL
EANM established EANM Forschungs GmbH, also known as EANM Research Ltd. (EARL), in 2006 to promote standardised quantification in nuclear medicine imaging.[20] As a subsidiary of EANM, EARL's primary goal is to enhance nuclear medicine practice, drive scientific initiatives, and facilitate clinical research projects.[21]
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
